Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016250 · ClinicalTrials.gov registry record · Phase 2
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00016250: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00016250 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016250, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of Ro 31-7453 in treating patients who have recurrent or refractory metastatic colorectal cancer.
Interventions
- DRUG MKC-1
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016250
The ClinicalTrials.gov registry entry for NCT00016250 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MKC-1 is the first listed.
NCT00016250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016250 about?
NCT00016250 is a clinical study titled "Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of Ro 31-7453 in treating patients who have recurrent or refractory metastatic colorectal...
What is the current status of trial NCT00016250?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00016250?
The interventions under investigation include: MKC-1 (DRUG).
Who is sponsoring clinical trial NCT00016250?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.